The agents listed below are currently under investigation. Their safety and effectiveness have not yet been established.
Poster
Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and tumors with androgen receptor (AR) 878/875 mutations
This website is intended for US Healthcare Professionals. It includes educational resources related to Arvinas’ investigational agents, research, and therapeutic areas of interest.
By selecting continue below, you acknowledge the information above and certify that you are a US Healthcare Professional (HCP).
